News.

Memery Crystal advise Graft Polymer (UK) plc in first LSE Main Market listing of 2022

10/01/2022

At a glance

In the first Main Market listing on the LSE of 2022, Memery Crystal has advised Graft Polymer (UK) plc, a business focussed on the development of polymer modification, bio/food supplements and drug delivery systems, on its listing and £5m placing.

Established in 2017 by a group of polymer technology experts and venture capitalists, Graft Polymer’s products address customer needs across a wide range of end use markets, from automotive through to medical. The business has distribution relationships with multiple partners globally, including distributors and agents in Europe, India and Russia.

The fundraising of £5m will fund accelerated growth, expand the Group’s research and production facility in Slovenia to meet rising customer demand, upgrade existing facilities to enable future IP registration, and increase both inventory and marketing opportunities following expected increased sales.

The Memery Crystal team on this deal was led by our senior ECM partner Nick Davis and senior associate Robert Black, who were assisted by solicitor Hannah Maxwell and paralegal Priya Morzeria. Turner Pope Investments (TPI) acted as the sole broker in relation to the admission and placing.

Commenting on the listing, Nick Davis said: “Graft Polymer is a highly innovative business with strong ESG credentials and intellectual property holding several patent applications. This listing is an exciting milestone for the business as it continues to provide novel products and solutions to a range of industries. We wish them every success with their expansion plans and look forward to continuing to support them.

Roby Zomer, Chairman of Graft Polymer (UK) said: “It has been a pleasure working with the Memery Crystal team on the listing of Graft Polymer. Nick and the team have supported us over a 2-year journey and helped us solve challenging legal and commercial issues along the way. We look forward to continued assistance on our journey as a listed company.”

Learn more

Nick Davis
Close

Contact Nick Davis

    Please complete all fields

    • ?

      I will use your email address to contact you in reference to your message. We will not pass this on to any 3rd parties, in accordance with our terms.

    Robert Black
    Close

    Contact Robert Black

      Please complete all fields

      • ?

        I will use your email address to contact you in reference to your message. We will not pass this on to any 3rd parties, in accordance with our terms.

      Latest news

      View all news